The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  The Lancet Respiratory Medicine

• Publication date

  2014-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S2213-2600(13)70259-5PMID 24503265
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• β2 Agonist for the Treatment of Acute Lung Injury: A Systematic Review and Meta-analysis

  2014cited by this paper
• Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials

  2013cited by this paper
• Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury

  2013cited by this paper
• High-Frequency Oscillation for Acute Respiratory Distress Syndrome

  2013cited by this paper
• High-frequency oscillation for acute respiratory distress syndrome.

  2013cited by this paper
• Purinergic signaling during inflammation.

  2012cited by this paper
• Acute Respiratory Distress Syndrome The Berlin Definition

  2012cited by this paper
• Clinical review: Early treatment of acute lung injury - paradigm shift toward prevention and treatment prior to respiratory failure

  2012cited by this paper
• Extracorporeal membrane oxygenation in adult acute respiratory distress syndrome.

  2011cited by this paper
• An updated study-level meta-analysis of randomised controlled trials on proning in ARDS and acute lung injury

  2011cited by this paper
• The acute respiratory distress syndrome: pathogenesis and treatment.

  2011cited by this paper
• Functional disability 5 years after acute respiratory distress syndrome.

  2011cited by this paper
• Systemic and bronchoalveolar cytokines as predictors of in-hospital mortality in severe community-acquired pneumonia.

  2010cited by this paper
• Neuromuscular blockers in early acute respiratory distress syndrome.

  2010cited by this paper
• Therapeutic strategies for severe acute lung injury

  2010cited by this paper
• Adenosine A2B receptors are highly expressed on murine type II alveolar epithelial cells.

  2009cited by this paper
• Review of A Large Clinical Series: Association of Cumulative Fluid Balance on Outcome in Acute Lung Injury: A Retrospective Review of the ARDSnet Tidal Volume Study Cohort

  2009cited by this paper
• Cost-effectiveness of implementing low-tidal volume ventilation in patients with acute lung injury.

  2009cited by this paper
• The adenosinergic immunomodulatory drugs.

  2009cited by this paper
• The prototype endothelial marker PAL-E is a leukocyte trafficking molecule.

  2009cited by this paper
• Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS‐induced PMN trafficking into the lungs

  2009cited by this paper
• A3 adenosine receptor signaling influences pulmonary inflammation and fibrosis.

  2008cited by this paper
• MxA protein assay for optimal monitoring of IFN‐β bioactivity in the treatment of MS patients

  2008cited by this paper
• A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice.

  2008cited by this paper
• Cell Traffic and the Lymphatic Endothelium

  2008cited by this paper
• Acute lung injury and the acute respiratory distress syndrome: a clinical review.

  2007cited by this paper
• IFN‐β protects from vascular leakage via up‐regulation of CD73

  2007cited by this paper
• Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies

  2007cited by this paper
• Physiological roles for ecto-5’-nucleotidase (CD73)

  2006cited by this paper
• Incidence and outcomes of acute lung injury.

  2005cited by this paper
• Cell-surface enzymes in control of leukocyte trafficking

  2005cited by this paper
• Prognostic determinants of acute respiratory distress syndrome in adults: Impact on clinical trial design

  2005cited by this paper
• Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury*

  2005cited by this paper
• Measurement of MxA mRNA or protein as a biomarker of IFNβ bioactivity

  2003cited by this paper
• Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers.

  2000cited by this paper
• Pharmacokinetics and Pharmacodynamics of IFN-β1a in Healthy Volunteers

  2000cited by this paper
• Regulation of Endothelial CD73 by Adenosine: Paracrine Pathway for Enhanced Endothelial Barrier Function1

  2000cited by this paper
• Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time.

  1995cited by this paper
• Clinical Investigations in Critical CarePersistent Elevation of Inflammatory Cytokines Predicts a Poor Outcome in ARDS: Plasma IL-1β and IL-6 Levels Are Consistent and Efficient Predictors of Outcome Over Time

  1995cited by this paper
• APACHE II: a severity of disease classification system.

  1985cited by this paper
• APACHE II: A severity of disease classification system

  1985cited by this paper

• Targeting CD73 and correcting adenosinergic signaling in critically ill patients

  2026influential citation
• Multicenter randomized trial assessing efficacy and safety of aerosolized dornase Alfa in COVID-19 ARDS

  2025cites this paper
• Identification of HIF1A as a therapeutic target during SARS-CoV-2–associated lung injury

  2025cites this paper
• Clinical management of sepsis-associated acute respiratory distress syndrome: current evidence and future directions

  2025cites this paper
• Integrative omics and multi-cohort identify IRF1 and biological targets related to sepsis-associated acute respiratory distress syndrome

  2025cites this paper
• The Interplay between Oral, Nasal, Lungs and Gut Microbiome Ecology in Coronavirus Disease 2019 (COVID-19) Infection

  2025cites this paper
• Investigational pharmacological agents for the treatment of ARDS

  2024cites this paper
• The endothelium: gatekeeper to lung ischemia-reperfusion injury

  2024cites this paper
• CD73: agent development potential and its application in diabetes and atherosclerosis

  2024cites this paper
• Multi-omics analysis reveals the interplay between pulmonary microbiome and host in immunocompromised patients with sepsis-induced acute lung injury

  2024cites this paper
• Steroids and Immunomodulatory Therapies for Acute Respiratory Distress Syndrome.

  2024cites this paper
• An update on the pharmacological management of acute respiratory distress syndrome

  2024cites this paper
• Inhibiting Eph/ephrin signaling reduces vascular leak and endothelial cell dysfunction in mice with sepsis

  2024cites this paper
• Immunomodulatory approaches in managing lung inflammation in COVID‐19: A double‐edge sword

  2023cites this paper
• Adjunctive Therapies in Acute Respiratory Distress Syndrome.

  2023cites this paper
• Unraveling the Intricacies of CD73/Adenosine Signaling: The Pulmonary Immune and Stromal Microenvironment in Lung Cancer

  2023cites this paper
• Anti-inflammatory therapies for acute respiratory distress syndrome

  2023cites this paper
• Decreased circulating CD73 and adenosine deaminase are associated with disease severity in hospitalized patients with COVID-19

  2023cites this paper
• Interferon-β alleviates sepsis by SIRT1-mediated blockage of endothelial glycocalyx shedding

  2023cites this paper
• CD73: Friend or Foe in Lung Injury

  2023cites this paper
• Polymorphism in interferon alpha/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19

  2023cites this paper
• Challenges in ARDS Definition, Management, and Identification of Effective Personalized Therapies

  2023cites this paper
• Inhibition of KLF6 reduces the inflammation and apoptosis of type II alveolar epithelial cells in acute lung injury.

  2022cites this paper
• Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials

  2022cites this paper
• Pharmacologic therapies of ARDS: From natural herb to nanomedicine

  2022cites this paper
• Polymorphism in IFNAR contributes to glucocorticoid response and outcome in ARDS and COVID-19

  2022cites this paper
• Immune Modulation in Sepsis, ARDS, and Covid-19 - The Road Traveled and the Road Ahead.

  2022cites this paper
• Efficacy and safety of Interferon-beta 1a in the management of the outpatients with mild to moderate COVID-19 (A preliminary study)

  2022cites this paper
• Endothelial dysfunction: a therapeutic target in bacterial sepsis?

  2021cites this paper
• Reflections on Critical Care’s Past, Present, and Future

  2021cites this paper
• A short review of CD73 Role in Cancer

  2021cites this paper
• Potential therapeutics in pediatric acute respiratory distress syndrome: what does the immune system have to offer? A narrative review

  2021cites this paper
• Potential Prophylactic Treatments for COVID-19

  2021cites this paper
• Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection

  2021cites this paper
• Efficacy of Interferon β-1a in Treatment of Hospitalized COVID-19 Patients; SBMU Taskforce on the COVIFERON Study

  2021cites this paper
• Intravenous Interferon-β1a for the Treatment of Ischemia-Reperfusion Injury in Acute Myocardial Infarct in Pigs.

  2021cites this paper
• Timing of Anti-viral therapy in COVID-19: Key to success.

  2021cites this paper
• SARS CoV-2: Progression and treatment protocols – An overview

  2021cites this paper
• Bioinformatic Approaches for Identification of Potential Repurposable Drugs in COVID-19

  2021cites this paper
• The Role of Interferon Beta Administration in COVID-19 Treatment

  2021cites this paper
• The relationship between soluble CD73 and the incidence of septic shock in severe sepsis patients: a cross-sectional analysis of data from a prospective FINNAKI study

  2021cites this paper
• Unsuccessful and Successful Clinical Trials in Acute Respiratory Distress Syndrome: Addressing Physiology-Based Gaps

  2021cites this paper
• Study of the effects of interferon β−1a on hospitalized patients with COVID‐19: SBMU Taskforce on the COVIFERON study

  2021cites this paper
• Induction of CD73 prevents death after emergency open aortic surgery for a ruptured abdominal aortic aneurysm: a randomized, double-blind, placebo-controlled study

  2021cites this paper
• Role of the adaptive immune response in sepsis

  2020cites this paper
• Lack of Clinical Benefit of Interferon β-1a Among Patients With Severe Acute Respiratory Distress Syndrome: Time to Overhaul Drug Trials in ARDS?

  2020cites this paper
• Effect of Intravenous Interferon β-1a on Death and Days Free From Mechanical Ventilation Among Patients With Moderate to Severe Acute Respiratory Distress Syndrome: A Randomized Clinical Trial.

  2020cites this paper
• Interferon-β-1a for patients with moderate to severe acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials.

  2020cites this paper
• Type 1 interferons as a potential treatment against COVID-19

  2020cites this paper
• Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung

  2020cites this paper
• Circulating MiRNA 887 is Differentially Expressed in ARDS and Modulates Endothelial Function.

  2020cites this paper
• Acute lung injury.

  2020cites this paper
• Efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia, a multicenter, randomized, double-blind, placebo-controlled trial

  2020cites this paper
• The Rationale for Potential Pharmacotherapy of COVID-19

  2020cites this paper
• Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial

  2020cites this paper
• COVID-19 pandemic: A review based on current evidence

  2020influential citation
• Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?

  2020cites this paper
• Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial

  2020cites this paper
• Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena

  2020cites this paper
• Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review

  2020cites this paper
• WKYMVm ameliorates acute lung injury via neutrophil antimicrobial peptide derived STAT1/IRF1 pathway.

  2020cites this paper
• Treatment of Covid-19: A review

  2020cites this paper
• Identification of atypical mitogen-activated protein kinase MAPK4 as a novel regulator in acute lung injury

  2020cites this paper
• An overview of key potential therapeutic strategies for combat in the COVID-19 battle

  2020cites this paper
• Sexual Dimorphism in Patients with COVID-19: Review

  2020cites this paper
• Approaches for the Treatment of SARS-CoV-2 Infection: A Pharmacologic View and Literature Review

  2020cites this paper
• NFKB1/NR3C1-MAPK4 axis regulates the pathology of acute lung injury

  2020cites this paper
• Bioinformatic approaches towards identification of potential repurposable drugs for COVID-19

  2020cites this paper
• Identi cation of atypical mitogen-activated protein kinase MAPK4 as a novel regulator in acute lung injury

  2020cites this paper
• : Efficacy and safety of interferon β -1a in treatment of severe COVID-19: A randomized clinical trial

  2020cites this paper
• In Brief.

  2020cites this paper
• Integrating molecular pathogenesis and clinical translation in sepsis-induced acute respiratory distress syndrome.

  2019cites this paper
• Purinergic Signaling in Pulmonary Inflammation

  2019cites this paper
• Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function

  2019cites this paper
• Immunometabolic Dysfunction of Natural Killer Cells Mediated by the Hypoxia-CD73 Axis in Solid Tumors

  2019cites this paper
• Enzyme activity of circulating CD73 in human serum.

  2019cites this paper
• CD73; a key ectonucleotidase in the development of breast cancer: Recent advances and perspectives

  2019cites this paper
• Cell type- and tissue-specific functions of ecto-5'-nucleotidase (CD73).

  2019cites this paper
• Excessive Extracellular ATP Desensitizes P2Y2 and P2X4 ATP Receptors Provoking Surfactant Impairment Ending in Ventilation-Induced Lung Injury

  2018cites this paper
• Sepsis and septic shock.

  2018cites this paper
• Role of complement C5a and histones in septic cardiomyopathy

  2018cites this paper
• The Role of Extracellular Adenosine Generation in the Development of Autoimmune Diseases

  2018cites this paper
• Infant cardiopulmonary bypass: CD73 kinetics, association with clinical outcomes, and influence on serum adenosine production capacity

  2018cites this paper
• Recent advances in understanding acute respiratory distress syndrome

  2018cites this paper
• Novel Interventions: What's New and the Future.

  2018cites this paper
• Early-phase Innate Immune Suppression in Murine Severe Sepsis Is Restored with Systemic Interferon-&bgr;

  2018cites this paper
• IFN‐&bgr; Improves Sepsis‐related Alveolar Macrophage Dysfunction and Postseptic Acute Respiratory Distress Syndrome‐related Mortality

  2018influential citation
• Acute Respiratory Distress Syndrome: Bench‐to‐Bedside Approaches to Improve Drug Development

  2018cites this paper
• Recombinant IFN-β for Postseptic Acute Lung Injury-What's the Mechanism?

  2018cites this paper
• Complement and sepsis‐induced heart dysfunction

  2017cites this paper
• Purinergic signalling links mechanical breath profile and alveolar mechanics with the pro-inflammatory innate immune response causing ventilation-induced lung injury

  2017cites this paper
• Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute respiratory distress syndrome: study protocol for a randomized controlled trial

  2017cites this paper
• GOLDEN anniversary of the acute respiratory distress syndrome: still much work to do!

  2017cites this paper
• Human vascular progenitor cells derived from renal arteries are endothelial-like and assist in the repair of injured renal capillary networks.

  2017cites this paper
• Stem Cell–based Therapies for Sepsis

  2017cites this paper
• The Oxygen Paradox, the French Paradox, and age-related diseases

  2017cites this paper
• Lateral flow immunoassay with upconverting nanoparticle‐based detection for indirect measurement of interferon response by the level of MxA

  2017cites this paper
• Fifty Years of Research in ARDS. Is Acute Respiratory Distress Syndrome a Preventable Disease?

  2017cites this paper
• The pulmonary endothelium in acute respiratory distress syndrome: insights and therapeutic opportunities

  2016cites this paper
• Other Community Respiratory Viruses

  2016cites this paper